Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.53 | 6.68 | 1.89 | -2.22 |
| FCF Yield | -10.77% | -0.49% | -0.92% | -1.03% |
| EV / EBITDA | -11.05 | -199.82 | -87.51 | -65.39 |
| Quality | ||||
| ROIC | -166.66% | -52.31% | -54.94% | -112.50% |
| Gross Margin | 100.00% | 100.00% | 21.72% | -251.23% |
| Cash Conversion Ratio | 0.75 | 1.01 | 0.78 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.02% | 76.16% | – | – |
| Free Cash Flow Growth | -12.43% | -47.77% | -49.11% | -27.43% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | -0.07 | 0.53 | 1.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -23.79 | -894.88 | -38.41 |